Glycopeptides and Other Agents Used to Treat Gram-Positive Cocci

Chapter

Abstract

Glycopeptide antibiotics are a class of agents, composed of glycosylated cyclic or polycyclic peptides. Clinically useful glycopeptides include vancomycin, teicoplanin, dalavancin, and telavancin.

Keywords

Fermentation Pneumonia Diarrhea Neutropenia Streptomyces 

Further Reading

  1. Arias, C. A., Contreras, G. A., & Murray, B. E. (2010). Management of Multi-Drug Resistant Enterococcal Infections. Clin Microbiol Infect.Google Scholar
  2. Credito, K. L., & Appelbaum, P. C. (2004). Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother, 48(11), 4430–4434.PubMedCrossRefGoogle Scholar
  3. Curcio, D. (2010). Resistant pathogen-associated skin and skin-structure infections: antibiotic options. Expert Rev Anti Infect Ther, 8(9), 1019–1036.PubMedCrossRefGoogle Scholar
  4. Dificid® oral tablets [package insert]. San Diego, CA: Optimer Pharmaceuticals Inc, April, 2011.Google Scholar
  5. Di Paolo, A., Malacarne, P., Guidotti, E., Danesi, R., & Del Tacca, M. (2010). Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet, 49(7), 439–447.PubMedCrossRefGoogle Scholar
  6. Guskey, M. T., & Tsuji, B. T. (2010). A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy, 30(1), 80–94.PubMedCrossRefGoogle Scholar
  7. Kollef, M. H. (2009). New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc, 11(4), 282–286.PubMedGoogle Scholar
  8. Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., et al. (2011). Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis, 52(3), 285–292.PubMedCrossRefGoogle Scholar
  9. Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., et al. (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med, 364(5), 422–431.PubMedCrossRefGoogle Scholar
  10. Nailor, M. D., & Sobel, J. D. (2009). Antibiotics for gram-positive bacterial infections: ­vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am, 23(4), 965–982, ix.Google Scholar
  11. Pfeiffer, R. R. (1981). Structural features of vancomycin. Rev Infect Dis, 3 suppl, S205-209.PubMedGoogle Scholar
  12. Rybak, M. J. (2006). The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect, 12 Suppl 1, 24–32.PubMedCrossRefGoogle Scholar
  13. Saravolatz, L. D., Stein, G. E., & Johnson, L. B. (2009). Telavancin: a novel lipoglycopeptide. Clin Infect Dis, 49(12), 1908–1914.PubMedCrossRefGoogle Scholar
  14. Sullivan, K. M., & Spooner, L. M. (2010). Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection. Ann Pharmacother, 44(2), 352–359.PubMedCrossRefGoogle Scholar
  15. Welte, T., & Pletz, M. W. (2010). Antimicrobial treatment of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents, 36(5), 391–400.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Massachusetts Medical SchoolWorcesterUSA
  2. 2.UMass Memorial Health Care Clinical Professor of MedicineUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations